Summary
Objective: To evaluate and compare the effects or oral and transdermal estrogen replacement therapy on biochemical markers of bone resorption in early postmenopausal women
Design: Controlled, randomized group comparison.
Setting: Outpatient clinic for menopausal women and research into osteoporosis.
Subjects: Sixty healthy women menopausal for less than 5 years and who had never received any medications interfering with bone metabolism.
Interventions: The 60 women were randomly allocated to 3 months therapy with either oral conjugated estrogens (0.625 mg/day) (n = 28) or transdermal estradiol (50 jig/day) (n = 32) in cyclical combination with medroxyprogesterone acetate (5 mg/day).
Main outcome measures: Traditional (urinary calcium/creatinine and hydroxyproline/creatinine) and the new specific (urinary pyridinoline/creatinine and deoxypyridinoline/creatinine) markers of bone resorption were determined before and after 3 months of treatment.
Results: In both groups, circulating levels of estrone and estradiol were significantly (P < 0.001) increased during treatment. In women treated with oral conjugated equine estrogens, urinary calcium/creatinine and hydroxyproline/creatinine ratios were significantly (P < 0.05) reduced. Pyridinoline/creatinine ratio fell from 69.1 (4) [mean (SEM)] to 50 (4) μmol/μmol (P < 0.01) and deoxypyridinoline/creatinine ratio fell from 10.8 (1) [mean (SEM)] to 8.3 (0.8) μmol/μmol (P < 0.01). In the group treated with transdermal estradiol, urinary hydroxyproline/creatinine ratio was significantly (P < 0.05) reduced. Pyridinoline/creatinine ratio fell from 66.3 (4) [mean (SEM)] to 46.2 (3) μmol/μmol (P < 0.01) and deoxypyridinoline/creatinine ratio fell from 11.5 (1.5) [mean (SEM)] to 7.7 (0.6) μmol/μmol (P < 0.01). There were no differences between the evolution of the biochemical variables in the two groups.
Conclusion: These results suggest that oral conjugated equine estrogens and transdermal estradiol, in the given doses, are equally effective in reducing postmenopausal bone resorption.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Riis BJ, Rodbro O, Christiansen C (1986) The role of serum concentrations of sex steroids and bone turnover in the development and occurrence of postmenopausal osteoporosis. Calcif Tissue Int 38:318–322
Lindsay R, Hart DM, Forrest C, Baird C (1980) Prevention of spinal osteoporosis in oophorectomized women. Lancet ii:1151–1153
Christiansen C, Christensen MS, Mac Nair P, Hagen C, Stocklumd K, Transbol I (1980) Prevention of early postmenopausal bone loss: controlled 2-year study in 315 normal females. Eur J Clin Invest 10:273–279
Horsman A, Jones M, Francis R, Nordin C (1983) The effect of estrogen dose on postmenopausal bone loss. N Engl J Med 309:1405–1407
Huppert LC (1987) Hormonal replacement therapy: benefits, risks, doses. Med Clin North Am 71:23–39
Judd H (1987) Efficacy of transdermal estradiol. Am J Obstet Gyn 156:1326–1331
Ribot C, Tremollieres F, Pouilles JM, Louvet JP, Peyron (1989) Preventive effects of transdermal administration of 17beta-estradiol on postmenopausal bone loss: a 2-year prospective study. Gynecol Endocrinol 3:259–268
Adami S, Suppi R, Bertoldo F, Rossini M, Residori M, Maresca V, Locascio V (1989) Transdermal estradiol in the treatment of postmenopausal bone loss. Bone Miner 7:79–86
Stevenson JC, Cust MP, Gangar KF, Hillard TC, Lees B, Whitehead MI (1990) Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet ii:265–269
Delmas PD, Donnez J, Chapuy MC, Smets M, Meunier PJ (1990) Short-term effects of transdermal 17beta-oestradiol (ESTRADERM TTS°) on bone metabolism in oophorectomized women: a placebo-controlled study. In: Christiansen C, Overgaard K (eds) Osteoporosis 1990. Osteopress ApS Publ, Copenhagen, pp 1985–1990
Lufkin EG, Hodgson SF, Kotowicz MA, O'Fallon WM, Wahner HW, Riggs BL (1990) The use of transdermal estrogen in treatment of osteoporosis. In: Christiansen C, Overgaard K (eds) Osteoporosis 1990. Osteopress ApS Publ, Copenhagen, pp 1995–1998
Uebelhart D, Gineyts E, Chapuy MC, Delmas PD (1990) Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner 8:87–96
Nordin BEC (1978) Diagnostic procedure in disorders of calcium metabolism. Clin Endocrinol 8:55–67
Zerbe GO (1979) Randomization analysis of the completely randomized design extend to growth and response curves. J Am Statist Assoc 74:215–221
Ettinger B, Genant HK, Cann CE (1985) Long-term estrogen therapy prevents bone loss and fracture. Ann Intern Med 102:319–324
Hutchinson TA, Polanski JM, Feinstein AR (1979) Postmenopausal oestrogens protect against fracture of hip and distal radius. Lancet ii:705–709
Komm BS, Terpening CM, Benz DJ, Graeme KA, Gallegos A, Korc M, Greene GL, O'Malley BW, Haussler MR (1988) Estrogen binding, receptor mRNA and biologic response in osteoblast-like osteosarcoma cells. Science 241:81–84
Young MM, Nordin BEC (1967) Effects of natural and artificial menopause on plasma and urinary calcium and menopause. Lancet ii:118–120
Nordin BEC, Polley KJ (1987) Metabolic consequences of the menopause. A cross-sectional, longitudinal and intervention study on 557 normal postmenopausal women. Calcif Tissue Int 41:S1:1–60
Lindsay R, Hart DM, Clark DM (1984) The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol 63:759–763
Ouyang PC, Chow SN, Huang SC, Hsieh CY (1986) Effect of estrogen (Premarin) replacement therapy on serum level of total estrogen and urinary excretion of calcium and hydroxyproline in postmenopausal Chinese women. Proc Natl Sci Counc B ROC 10:162–166
Black D, Farquarson C, Robin SP (1989) Excretion of pyridinium cross-links of collagen in ovariectomized rats as urinary markers for increased bone resorption. Calcif Tissue Int 44:343–347
Whittaker PG, Morgan MRA, Dean PDG (1980) Serum equilin, oestrone and oestradiol levels in postmenopausal women receiving conjugated equine oestrogens (Premarin). Lancet i:14–16
Varma TR, Everard D, Hole D (1985) Effect of natural estrogen on the serum level of follicle-stimulating hormone (FSH), estradiol and estrone in postmenopausal women and its effect on endometrium. Acta Obstet Gynecol Scand 64:105–109
Reginster JY, Sarlet N, Deroisy R, Albert A, Gaspard U, Franchimont P (1992) Minimal levels of serum estradiol to prevent postmenopausal bone loss. Calcif Tissue Int 51:340–343
Powers MS, Schenkel L, Darley PE, Good WR (1985) Pharmacokinetics and pharmacodynamics of transdermal dosage forms of l7beta-estradiol: comparison with conventional oral estrogens used for hormone replacement. Am J Gyn Obstet 152:1099–1106
Selby PL, Peacock M (1986) Dose dependent response of symptoms, pituitary, and bone to transdermal oestrogen in postmenopausal women. Br Med J 293:1337–1339
Steingold KA, Laufer L, Chetkowski RJ, Defazio JD, Matt DW, Meldrum DR, Judd HL (1985) Treatment of hot flashes with transdermal estradiol administration. J Clin Endocrinol Metab 61:627–632
Chetkowski RJ, Meldrum DR, Steingold KA, Randle D, Lu JK, Eggena P, Hershman JM, Alkiaersig NK, Fletcher AP, Judd HL (1986) Biologic effects of transdermal estradiol. N Engl J Med 314:1615–1620
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Reginster, J.Y., Christiansen, C., Dequinze, B. et al. Effect of transdermal l7β-estradiol and oral conjugated equine estrogens on biochemical parameters of bone resorption in natural menopause. Calcif Tissue Int 53, 13–16 (1993). https://doi.org/10.1007/BF01352008
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF01352008